Understanding Haemochromatosis Arthropathy (HA)

Haemochromatosis Arthropathy (HA) is a painful joint disease affecting up to 87% of individuals with Haemochromatosis. Despite its prevalence and severity, HA remains under-recognised, lacks disease-modifying treatments, and the exact role of iron overload in its development is still unclear.

Recent Research Breakthrough

Professor Patrick Kiely, alongside a team of diverse experts and patient partners, has made a significant stride in the study of HA by developing the first-ever classification criteria. This allows for a more accurate identification of patients for research purposes, paving the way for heightened understanding and potential advancements in treatment.

Introducing the Classification Criteria

The newly developed model comprises 8 core variables that effectively distinguish HA from other conditions such as osteoarthritis (OA) and calcium pyrophosphate deposition disease (CPPD).

• Total Score of 5 out of 11 achieves 93.3% specificity and 71.4% sensitivity for HA diagnosis.
• Key radiographic signs include:
• Grade 3 joint space narrowing
• Subchondral cysts at MCP and ankle joints
• Hook osteophytes at MCP 3 and the anterior distal tibia

Future Implications

These advancements mark a pivotal moment for HA research, enabling deeper exploration into the links between iron overload and joint damage. Furthermore, better patient identification will accelerate studies, laying the foundation for more targeted treatment options. Thank you for sharing your work with us, Professor Kiely.